Basic Information
Bretaris Genuair
Regulatory Information
EMEA/H/C/002706
Authorised
July 20, 2012
20
February 25, 2025
Company Information
the netherlands
Gustav Mahlerplein 2 1082 MA Amsterdam
Covis Pharma Europe BV
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Bretaris Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Overview Summary
This is a summary of the European public assessment report (EPAR) for Bretaris Genuair. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Bretaris Genuair. For practical information about using Bretaris Genuair, patients should read the package leaflet or contact their doctor or pharmacist.